Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 24, 2020 | Convertable Note | $827.33K | 1 | — | — | Detail |
Apr 25, 2018 | Series B | $60M | 9 |
![]() |
— | Detail |
Feb 17, 2016 | Series A | $26M | 2 |
![]() ![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series B |
![]() |
— | Convertable Note |
|
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
|
— | Series B |